This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Medac Pharma, Inc. Announces The Issuance Of U.S. Patent For Treating Autoimmune Diseases With Concentrated Methotrexate Solutions Of More Than 30 Mg/ml

CHICAGO, March 11, 2014 /PRNewswire/ -- Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announces the issuance, via its parent company, medac GmbH, of U.S. patent 8,664,231 (the '231 patent) by the United States Patent and Trademark Office.  The patent, entitled "Concentrated Methotrexate Solutions," is directed to a method for the treatment of inflammatory autoimmune diseases by subcutaneously administering methotrexate (MTX) at a concentration of more than 30 mg/ml. 

Medac Pharma and medac GmbH also announce the filing of a lawsuit in the United States District Court in New Jersey against Antares Pharma, Inc. (NASDAQ: ATRS), LEO Pharma A/S and LEO Pharma Inc. for infringement of the '231 patent by their making, selling and offering for sale of Otrexup™ (methotrexate) injection products for treating forms of rheumatoid arthritis, polyarticular idiopathic arthritis and psoriasis.

"The grant of the '231 patent in the U.S. is an important step in our ongoing development of MPI-2505, which we believe has the potential to be a best-in-class treatment option for rheumatoid arthritis and psoriasis," said Ms. Terri Shoemaker, President and CEO of Medac Pharma, Inc.  "A key advantage to MPI-2505 is its wide range of methotrexate dosing options, which are designed to improve bioavailability and overcome tolerability issues associated with today's oral methotrexate therapies.  Providing patients with a ready-to-use autopen for the administration of MPI-2505 in reduced drug volumes also addresses the stigmas associated with injectable medicines.  As such, the grant of the '231 patent is a significant event for Medac Pharma, and we and our parent company, medac GmbH, plan to vigorously defend and enforce it."

About Medac Pharma, Inc.

Medac Pharma, Inc. is the wholly-owned subsidiary of medac GmbH, a well known and respected global pharmaceutical company that has been making scientific and therapeutic discoveries for more than 40 years.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 -1.15%
FB $117.58 0.73%
GOOG $693.01 0.29%
TSLA $240.76 -2.81%
YHOO $36.60 0.03%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs